Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H267

UPID:
VP33B_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H267; B3KQF6; Q96K14; Q9NRP6; Q9NSF3

BACKGROUND:
The Vacuolar protein sorting-associated protein 33B (VPS33B) is implicated in critical cellular processes such as protein trafficking to lysosomal compartments, membrane fusion reactions, and the sorting of specific cargos from the trans-Golgi network. Its interaction with VIPAS39 suggests a role in maintaining apical-basolateral polarity in epithelial cells.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Vacuolar protein sorting-associated protein 33B could open doors to potential therapeutic strategies for treating diseases like Arthrogryposis, renal dysfunction and cholestasis syndrome 1, and progressive familial intrahepatic cholestasis 12, by targeting the underlying genetic variants.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.